Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults

What this Trial Is About

Researchers are evaluating the effects of interventional treatments on older adults with symptomatic, severe tricuspid valve insufficiency. The study focuses on whether these treatments can improve kidney function and reduce related biomarkers. It also aims to assess changes in swelling, symptom severity, physical capacity, motor skills, daily activities, participation, and overall quality of life in these patients. The intervention under observation is the transcatheter edge-to-edge repair (TEER), a procedure used to treat tricuspid valve insufficiency. Participants will be assessed before and after this intervention. The study collects data at baseline, 6 months, 12 months, and 24 months to monitor changes over time. Participants will undergo various evaluations including kidney function tests, physical activity monitoring with the activPAL4 device, and exercise capacity measured by the 6-minute walk test. Additional assessments cover body mass index, hospitalizations due to heart failure, quality of life questionnaires, frailty scales, cognitive and emotional tests, muscle strength, and mobility. The study also tracks kidney-related outcomes such as acute kidney injury, dialysis initiation, and chronic kidney disease prevalence. Monitoring occurs throughout the study period to understand the impact of the intervention on multiple health aspects.

Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.